PF614 solution for Pharmacokinetics

Phase-Based Progress Estimates
PharmacokineticsPF614 solution - Drug
18 - 55
All Sexes
What conditions do you have?

Study Summary

This trial will study how the body processes oxycodone when given alone or with nafamostat, an antifungal drug.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

6 Primary · 4 Secondary · Reporting Duration: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,16,24,36,48 hours

24 hours
Pharmacokinetic C24 [Plasma concentration at 24 hours]
30 days
Incidence of Treatment-Emergent Adverse Effects [Safety and Tolerability]
pre-dose, 0.5,1,1.5,2,3,4,6,8,12,16,24,36,48 hours
Bioavailability AUC(0-inf)
Bioavailability AUC(0-last)
Bioavailability Cmax
Pharmacokinetic AUC [Area Under the Curve]
Pharmacokinetic AUC(0-last)
Pharmacokinetic Cmax [Maximum Plasma Concentration]
Pharmacokinetic T1/2 [Half-life]
Pharmacokinetic Tmax [Time to Maximum Plasma Concentration]

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

PF614 solution concomitantly with nafamostat
1 of 2
PF614 solution
1 of 2

Experimental Treatment

64 Total Participants · 2 Treatment Groups

Primary Treatment: PF614 solution · No Placebo Group · Phase 1

PF614 solution concomitantly with nafamostatExperimental Group · 3 Interventions: PF614 solution, Naltrexone Hydrochloride, Nafamostat Mesylate · Intervention Types: Drug, Drug, Drug
PF614 solutionExperimental Group · 2 Interventions: PF614 solution, Naltrexone Hydrochloride · Intervention Types: Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved

Trial Logistics


Participation is compensated

You will be compensated for participating in this trial.

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,16,24,36,48 hours

Who is running the clinical trial?

Ensysce BiosciencesLead Sponsor
5 Previous Clinical Trials
224 Total Patients Enrolled
1 Trials studying Pharmacokinetics
17 Patients Enrolled for Pharmacokinetics
National Institute on Drug Abuse (NIDA)NIH
2,245 Previous Clinical Trials
5,619,336 Total Patients Enrolled
4 Trials studying Pharmacokinetics
153 Patients Enrolled for Pharmacokinetics
Quotient SciencesIndustry Sponsor
40 Previous Clinical Trials
1,104 Total Patients Enrolled
1 Trials studying Pharmacokinetics
19 Patients Enrolled for Pharmacokinetics
Maricer Escalon, MDPrincipal InvestigatorSenior Medical Director, Quotient Sciences
Maria Bermudez, MDPrincipal InvestigatorSenior Medical Director, Quotient Sciences

Eligibility Criteria

Age 18 - 55 · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are a healthy male or non-pregnant, non-lactating female.
You are 18 to 55 years old.
You must be able to understand a written informed consent, which must be obtained prior to initiation of study procedures.